[June 29, 2016]

Global Canavan Disease Therapeutics Pipeline Report 2016 Featuring StemCells & Turing Pharmaceuticals - Research and Markets

Research and Markets has announced the addition of the "Canavan Disease - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Canavan Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Canavan Disease and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive avantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Canavan Disease Overview
3. Therapeutics Development
4. Pipeline Products for Canavan Disease - Overview
5. Pipeline Products for Canavan Disease - Comparative Analysis
6. Canavan Disease - Therapeutics under Development by Companies
7. Canavan Disease - Therapeutics under Investigation by Universities/Institutes
8. Canavan Disease Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Canavan Disease - Products under Development by Companies
13. Canavan Disease - Products under Investigation by Universities/Institutes
14. Canavan Disease - Companies Involved in Therapeutics Development

• StemCells, Inc.
• Turing Pharmaceuticals AG

For more information visit http://www.researchandmarkets.com/research/ptqhc2/canavan_disease

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006274/en/

[ Back To TMCnet.com's Homepage ]